RNAZ stock forecast, quote, news & analysis
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer... Show more
TransCode Therapeutics (RNAZ) Stock Analysis: RNA Oncology Pipeline Advances Toward Phase 2a Milestones
Key Takeaways
- RNAZ traded near $1.63 in late October 2026, roughly 4% above its level around 30 days earlier — a move below the 10% threshold that would signal a sharp directional shift.
- TransCode Therapeutics is a clinical-stage biotech developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers, with lead candidate TTX-MC138 targeting microRNA-10b.
- Phase 1a data showed no dose-limiting toxicities, with stable disease reported in 10 of 14 efficacy-evaluable patients; the program has advanced into a Phase 2a trial in ctDNA-positive colorectal cancer.
- Recent catalysts include a collaboration with Natera to support trial enrollment, a Phase 1a data presentation at ESMO Congress 2026, and a formal strategic review process led by Tungsten Advisors.
- The company remains a pre-revenue, small-cap developer with no approved products, carrying the elevated risk profile typical of early-stage biotechnology.
- Investors can review additional details, including Price Targets, Earnings, and Forecast, on dedicated analysis pages.
- For automated trading insights, explore Trending AI Robots.
Current Market Snapshot
TransCode Therapeutics shares have traded within a relatively contained range in recent weeks. In late October 2026, RNAZ closed near $1.63, compared with roughly $1.57 about 30 days earlier, representing a modest gain of approximately 4%. The stock continues to trade near the lower end of its 52-week range, which spans approximately $1.52 to $13.96, reflecting the significant repricing experienced by many pre-revenue biotech names over the past year.
As a micro-cap company with no product revenue, TransCode's share price is heavily influenced by clinical news flow, financing developments, and broader risk appetite across the biotechnology sector. The stock carries a beta above the broader market, underscoring its sensitivity to sentiment shifts. Trading volumes are modest, and the company maintains a relatively small public float, which can contribute to elevated price volatility around news events.
TransCode Therapeutics (RNAZ) Business Overview and Competitive Position
Headquartered in Boston, Massachusetts, TransCode Therapeutics is a clinical-stage oncology company focused on RNA-based therapeutics and immuno-oncology for high-risk and advanced cancers. Its lead candidate, TTX-MC138, is a first-in-class therapeutic designed to inhibit microRNA-10b (miR-10b), a microRNA widely regarded as a key regulator of metastatic cell viability across multiple tumor types, including breast, pancreatic, ovarian, and colorectal cancers.
The company's proprietary nanoparticle delivery platform is designed to deliver therapeutics to tumors beyond the liver, a longstanding challenge in the RNA field. TransCode's broader pipeline includes seviprotimut-L, a Phase 3 melanoma vaccine candidate with Fast Track and Orphan Drug designations, as well as preclinical programs such as TTX-siPDL1, TTX-RIGA, and UIO-524, an engineered oncolytic adenovirus being developed for muscle-invasive bladder cancer. Investors follow the stock for its differentiated RNA-delivery technology and a pipeline of catalysts extending through 2027.
Recent Developments Driving RNAZ
Several verified events shaped investor sentiment over the last 30 days. In late October 2026, TransCode presented updated Phase 1a clinical data for TTX-MC138 at the European Society for Medical Oncology (ESMO) Congress 2026, highlighting durable disease control and acceptable tolerability in patients with advanced solid tumors. The company also announced that its board had initiated a formal strategic process with Tungsten Advisors as financial advisor to evaluate options designed to maximize the value of TTX-MC138 and its oncology portfolio, including potential licensing, partnerships, or other transactions.
Earlier in the period, TransCode and Natera announced a collaboration to support enrollment in the Phase 2a trial of TTX-MC138, using Natera's Signatera test to identify patients with molecular residual disease following curative-intent therapy. The company also reported patent advancements in Australia and Japan strengthening its intellectual property position, and disclosed a leadership transition as CFO Tom Fitzgerald announced his retirement, with John Tattory named interim CFO. Collectively, these developments reinforced the clinical and strategic narrative without triggering a decisive directional move in the share price.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading systems from a broader universe of hundreds of AI-powered bots that trade thousands of tickers. Only top-performing and most relevant robots appear in this section, giving users a focused view of strategies that are currently attracting attention. The bots vary widely in strategy, timeframe, and performance metrics, allowing traders to compare approaches across different market conditions. The page is designed to help investors discover and evaluate algorithmic trading tools that align with their objectives. For those interested in automated insights, explore Trending AI Robots.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary driver for TransCode will be execution on the Phase 2a trial of TTX-MC138 in ctDNA-positive colorectal cancer. Management has guided toward preliminary results beginning in late 2026, with enrollment completion and a readout targeted for the second half of 2027. Investors will also monitor the outcome of the strategic process with Tungsten Advisors, which could result in a licensing agreement, partnership, or other transaction — though the company has cautioned that no transaction is assured.
Additional factors to watch include progress on seviprotimut-L's planned MELISSA confirmatory trial, IND-enabling work for UIO-524, and the company's cash runway, which management has stated could extend into late 2027 or early 2028 under its existing financing arrangements. Broader risks include the availability of capital for pre-revenue biotech companies, regulatory developments, and clinical execution. The next quarterly earnings report is scheduled for mid-November 2026.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RNAZ in upward trend: price may jump up because it broke its lower Bollinger Band on November 10, 2026
RNAZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 39 of 43 cases where RNAZ's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where RNAZ advanced for three days, in 160 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RNAZ as a result. In 71 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for RNAZ turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 31 similar instances when the indicator turned negative. In 28 of the 31 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RNAZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for RNAZ entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.893) is normal, around the industry mean (3.498). P/E Ratio (-0.030) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. RNAZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RNAZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology